- Home
- ORC vs TYRA Comparison
ORC vs TYRA Comparison
Compare ORC & TYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORC
- TYRA
- Stock Information
- Founded
- ORC 2010
- TYRA 2018
- Country
- ORC United States
- TYRA United States
- Employees
- ORC N/A
- TYRA N/A
- Industry
- ORC Real Estate Investment Trusts
- TYRA Biotechnology: Pharmaceutical Preparations
- Sector
- ORC Real Estate
- TYRA Health Care
- Exchange
- ORC Nasdaq
- TYRA Nasdaq
- Market Cap
- ORC 623.6M
- TYRA 666.4M
- IPO Year
- ORC 2013
- TYRA 2021
- Fundamental
- Price
- ORC $8.91
- TYRA $13.17
- Analyst Decision
- ORC Buy
- TYRA Strong Buy
- Analyst Count
- ORC 3
- TYRA 6
- Target Price
- ORC $9.50
- TYRA $30.50
- AVG Volume (30 Days)
- ORC 3.1M
- TYRA 254.2K
- Earning Date
- ORC 01-30-2025
- TYRA 03-18-2025
- Dividend Yield
- ORC 16.14%
- TYRA N/A
- EPS Growth
- ORC N/A
- TYRA N/A
- EPS
- ORC 0.58
- TYRA N/A
- Revenue
- ORC $54,406,000.00
- TYRA N/A
- Revenue This Year
- ORC N/A
- TYRA N/A
- Revenue Next Year
- ORC N/A
- TYRA N/A
- P/E Ratio
- ORC $15.50
- TYRA N/A
- Revenue Growth
- ORC N/A
- TYRA N/A
- 52 Week Low
- ORC $7.41
- TYRA $11.89
- 52 Week High
- ORC $9.08
- TYRA $29.60
- Technical
- Relative Strength Index (RSI)
- ORC 79.15
- TYRA 43.64
- Support Level
- ORC $8.25
- TYRA $12.27
- Resistance Level
- ORC $8.35
- TYRA $13.79
- Average True Range (ATR)
- ORC 0.15
- TYRA 0.71
- MACD
- ORC 0.06
- TYRA 0.03
- Stochastic Oscillator
- ORC 91.16
- TYRA 51.09
About ORC Orchid Island Capital Inc.
Orchid Island Capital Inc invests in residential mortgage-backed securities (RMBS) across the United States. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
About TYRA Tyra Biosciences Inc.
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNAPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. Its lead product candidate is TYRA 300, an FGFR3 selective inhibitor with an initial focus on patients with metastatic urothelial carcinoma of the bladder and urinary tract (mUC).